The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $27.71. MNMD has been the subject of a number of research analyst reports.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...
The firm decreased its portfolio allocation in MNMD by 19.12% over the last quarter ... Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved ...